Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab After CRT in Elderly ESCC
NCT06187597Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Mar 2024
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of toripalimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Sun Yat-sen University. Started Mar 2024; status: recruiting.
02
Drugs
toripalimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06187597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06187597.